Sandiṭṭhiko (@Sandiithiko) header
Sandiṭṭhiko (@Sandiithiko) profile picture

Investor of @IBRX for curing cancers

Joined November 2024
Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)Photo by Sandiṭṭhiko (@Sandiithiko)
The most Important Science of the decades is here and curing diseases and enhances longevity. Introducing CAR-NK Cells expressing PD-L1. The most Important and Useful Cells in our bodies to fight ALL types of Cancers and Infections. BioShield
2025 was the unveiling of the Bioshield Platform - Anktiva as foundation for killer cells. Now for 2026 unveil. Next element to Bioshield Platform - engineered NK cells to TARGET cancer. The CAR-NK in Phase 2 trials infused w/ Anktiva pubmed.ncbi.nlm.nih.gov/3243… See you at JPM26
204
12
3
66
25,267
Sandiṭṭhiko retweeted
Outstanding work, @DrPatrick and @ImmunityBio Every step forward in cancer research brings renewed hope to families. Together,let’s keep advancing innovation and fighting to save lives. $IBRX Let’s work toward giving more families hope and protecting more lives. #Anktiva #Biotech
4
13
3
103
2,129
Sandiṭṭhiko retweeted
Replying to @DrPatrick
@DrPatrick I believe that #anktiva and SenoMune-0257 will change the world. Go $IBRX !
5
11
3
138
3,526
It is Friday isn’t it? 😏⚡️🙋🏻‍♂️⚡️
38
352
3
3,165
22,873
🤔
52
310
13
893
13,211
Sandiṭṭhiko retweeted
⚠️ No es una escena de una película de terror, sino la cruda y dolorosa realidad que vive la población de Gaza.
226
8,783
166
14,522
149,911
Sandiṭṭhiko retweeted
Last week, we honored our Veterans. Now, we’re listening to what they shared about the challenges of accessing #NMIBC care. A new ImmunityBio survey conducted by @HarrisPoll found that 63% of veterans with NMIBC have faced treatment barriers, including long appointment waits (35%) and difficulty coordinating VA and non-VA care (27%). These statistics represent delays and uncertainty for people who've already given so much. Researching and working to expand treatment options for patients with NMIBC is part of how we're working to change that. Explore the full survey results: immunitybio.com/new-u-s-surv…
1
12
2
98
4,049
Sandiṭṭhiko retweeted
Treatment has started with @DrPatrick and the team at @ImmunityBio ($IBRX). It has been a JOURNEY to get to this place! Grateful beyond words for everyone involved and all the angels here that helped advocate. I can literally feel my entire immune system waking up. It's wild. The best I can hope is my story plays a role in expanding access for ALL patients that need these treatments. Won't stop until we get there.
36
54
5
382
8,946
Sandiṭṭhiko retweeted
Absolutely CRIMINAL They invented 96,000 patients that never existed…got The Lancet to publish it…and used it to kill a cheap drug overnight…so they could get Emergency Use Authorization for the ‘Covid Vaccine’…
609
11,611
557
22,990
249,158
Sandiṭṭhiko retweeted
$IBRX Goldman Sachs increased its ImmunityBio position by 27.69% in Q3, adding nearly 896,000 shares. As of September 30, 2026, Goldman held 4,129,906 shares, compared with 3,234,277 in the previous filing. That’s a meaningful increase in institutional exposure. Goldman is building its position, and that’s worth paying attention to. 👀📈
5
8
105
3,342
Sandiṭṭhiko retweeted
$IBRX Deloitte just named ImmunityBio the No. 2 fastest growing tech company in North America. Out of 500. Everyone will quote that ranking. We read the whole press release instead. At the end of the CEO's quote we found six words this company had not used in a year of releases. The award lands in a rough stretch. Sales dipped last quarter and the report didn't say why; the explanation only came a week later, on a London stage. Still no guidance. Longtime supporters are frustrated, and they are saying so out loud. We hear them. We do not share the mood. When the noise gets loud, we read. So before anyone quotes the ranking, here is what is actually in the November 19 release. THE NUMBER EVERYONE WILL QUOTE On November 18, Deloitte released its 2026 Technology Fast 500, its ranking of North America's fastest growing technology companies, now in its 32nd year. ImmunityBio: No. 2 of 500. Revenue growth of 47,103 percent, fiscal 2022 to fiscal 2025. A year ago it ranked No. 67. Here is the math inside that percentage: - 2022 revenue: $240,000. Pre-approval. Licensing and grants - 2025 revenue: $113 million. ANKTIVA on the market - That is 472x in three years Any company that goes from almost nothing to real sales posts a giant percentage. Geron, at No. 4, is the same story: first product launched in 2024. So hold the percentage loosely. The dollars are the real story: from a quarter of a million to 113 million in three years. THE SIX WORDS ALMOST EVERYONE WILL SKIP CEO Richard Adcock's quote in the release walks through the growth: 700 percent net product revenue growth in 2025, 92 percent through the first nine months of 2026, broader clinical adoption of ANKTIVA in the US and globally. Then it ends: "...expanding patient access, strengthening our global commercial presence, and delivering long-term value to our stockholders." Read the last six words again. "Delivering long-term value to our stockholders." WHY THE ENDING STOPPED US We went back through this year's record. The Q1, Q2 and Q3 earnings releases. The October approval announcement. The November trial results. The Jim Yong Kim appointment. Both London investor sessions from November 16. Every quote closes on the medicine: patients, access, clinical progress. The closest thing to investor language all year was "supporting long-term growth." Not one ends on stockholders. This one does. ONE SENTENCE IS NOT A STRATEGY The phrase itself is ordinary corporate language. In an award release it is almost expected. And we reviewed this year's record, not every page the company ever published. But press-release quotes are drafted, reviewed and signed off before they cross the wire. Endings are chosen. And in the exact month when the questions got loudest, an executive quote ends on the people who own the company. First time in anything we reviewed. THE FOUNDER SAID HIS VERSION THREE DAYS EARLIER The CEO is not the only one choosing words carefully. On November 16, three days before this press release, founder Patrick Soon-Shiong posted about the London conferences and the trial win. Read how his post ends: "Immunotherapy 2.0 slowly but surely." The same week. The same company. Two quote endings chosen at the top: slowly but surely, and long-term value. And this is not a new phrase for him. He used it about combination immunotherapy back in 2022. He used it about the science this January. On November 12 he wrote "Decades of quiet, private work" and "Over next 12 months much will be revealed... Stay tuned." Neither man is promising next quarter. In October we asked in these pages what this company's medicine could one day sell in a year. The $50 to $90 billion question. The founder shared that post himself. That question still stands. What changed this month is the timeframe the top of the company is speaking in. Long-term. Slowly. Surely. Nobody up there is selling instant miracles. They are asking for patience. And for the first time in anything we reviewed, they are saying it directly to the owners. THE SLIDES THAT CONNECT THE DOTS Our October post asked the long-run question with one comparison: Keytruda. Merck's checkpoint drug that grew from a single approval in 2014 into $31.7 billion a year. In London this month, ImmunityBio's own investor deck made the same comparison. Three slides in a row. KEYTRUDA printed next to ANKTIVA on the origin-story slide. Keytruda's 19 tumor types laid out approval by approval, 2014 to 2026, as the path a successor could follow. Then the checkpoint patent cliff that opens the door. When we drew that parallel in October, it was a thesis from the outside. In November it is on the company's own slides, shown to institutional investors. THE FAST VERSION EVERYONE IS DREAMING ABOUT Now the twist everyone is whispering about. On November 17, a small cancer-vaccine company called SELLAS announced its Phase 3 leukemia trial met its survival endpoint. The stock had closed at $7.47, after spending much of the year with roughly 30 percent of its float sold short. Before the market even opened, it was halted and reopened, and a market report that morning recorded prints as high as $34 on thin volume. Up over 350 percent at the peak, before the first regular trade. In the session it touched $24.89 and closed at $19.15, up 156 percent on the day. A lot of IBRX holders watched that and thought: that could be us. So let's say it plainly. Could that shape of day happen here? The ingredients exist. Short interest most recently reported around 31 percent of the float. And a calendar of hard catalysts ahead: the sBLA filing, then the trial numbers at a medical congress. Is it guaranteed? No. SELLAS did not jump because people wished for it. The data landed, and a crowded short side met it all at once. A catalyst has to land here too. And look at what happened next. From $34 in the premarket to $24 at the open. To $19.15 by the close. To $17.95 the day after. A squeeze is weather. It passes. What a company keeps is whatever its sales, its approvals and its pipeline can hold up. Without fundamentals underneath, even the wildest day gives itself back. So yes, the fast version is possible here. It is just not the plan. The plan is the one the founder and the CEO just put into words: slowly, surely, long-term. A spike would be a day to enjoy. The fundamentals are what remain after it. THE NEXT TEST IS ALREADY ON THE CALENDAR The sBLA for ANKTIVA plus BCG in BCG-naive bladder cancer is due at FDA before 2026 closes out. That is the timing management gave investors in London on November 16. When that release crosses the wire, go straight to the CEO quote and read how it ends. If it ends on stockholders again, this was not a slip of the pen. It is ImmunityBio learning to talk to the people who own it. And what both voices at the top of ImmunityBio are telling the people who own it is the same thing: from the ANKTIVA filing due before 2026 ends to everything on the road after it, this is a long game, and it is being played to be won. Patience is the plan.
11
18
5
138
8,118
Sandiṭṭhiko retweeted
21
673
15
4,457
873,119
Sandiṭṭhiko retweeted
ImmunityBio ranked No. 2 on the 2026 @Deloitte Technology Fast 500™, reflecting revenue growth of more than 47,000% from 2022 to 2025. Thank you to our employees and partners for their contributions to this milestone. Read the full announcement: immunitybio.com/immunitybio-… $IBRX #fast500
10
46
5
318
12,037
Sandiṭṭhiko retweeted
🇵🇸✊ Nuestra admiración y respeto, señor Cristiano Ronaldo.‼️Palestina libre‼️
Readers added context they thought people might want to know
El vídeo de Cristiano Ronaldo con una bandera de Palestina en el photocall del Balón de Oro no es real: está generado con inteligencia artificial y lleva la marca de agua de Sora, el generador de vídeos de OpenAI. maldita.es/desinfo/202607…
996
7,504
197
25,119
1,078,015
Sandiṭṭhiko retweeted
🤷‍♂️
124
433
23
1,637
34,300
Only for highest form of humans. Ordinary people go to hospitals.
Reminder that Ivermectin dosing in Cancer was developed at MD Anderson Cancer Center, Department of Leukemia This is for the Oncologists who don't read latest Cancer Research (we know you don't) 😃 And those who still think Ivermectin is a "horse dewormer" or a "made up treatment" 😂
56
Sandiṭṭhiko retweeted
$IBRX UBS Conference "The one that we're really excited about, and we've been working with this with ANKTIVA is now in sepsis. The PH II trial has now been fully authorized. We're working with sites like Cleveland Clinic +others around the country +world to be able to set that up. Two reasons that I'll say we're really excited about sepsis is, first, no one's been able to touch it. Our early work we've done in single patient INDs we've done have shown the exact effect we're looking for because if you look at sepsis, what happens, you've got this hyperinflammation phase and then they crash. Well, what's crashing? The lymphocytes..." "...If unfortunately, many people die. And if they don't, it can be a very long prognosis -- drawn-out event from those. So sepsis is one, while early, the teams that we've been working with, and again, Cleveland Clinic, when we presented this to them, they're like, this is one of the most exciting things we've seen because it impacts on all sides of this..."
1
7
23
1,733
Sandiṭṭhiko retweeted
Israel just bulldozed one of the most prosperous Palestinian farms near the Jordan Valley area This farm feeds 10,000s of people, and is a prominent source of food in the area
4,289
28,480
2,257
46,883
1,560,980
I know it, Big hands were stealing shares from retails $IBRX.
$IBRX Largest Adds in ImmunityBio in released 13F so far
1
1
38
1,215